Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H20FN3O4.ClH |
Molecular Weight | 397.828 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N4CCN(C)CC4
InChI
InChIKey=CAOOISJXWZMLBN-UHFFFAOYSA-N
InChI=1S/C18H20FN3O4.ClH/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21;/h7-8,10H,3-6,9H2,1-2H3,(H,24,25);1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C18H20FN3O4 |
Molecular Weight | 361.3675 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/1723377Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2688325
https://www.ncbi.nlm.nih.gov/pubmed/2688325
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1723377
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2688325
https://www.ncbi.nlm.nih.gov/pubmed/2688325
Ofloxacin is one of a new generation of fluorinated quinolones structurally related to nalidixic acid, primary mechanism of action is inhibition of bacterial DNA gyrase. It is an orally administered broad spectrum antibacterial drug active against most Gram-negative bacteria, many Gram-positive bacteria and some anaerobes. Clinical trials to date have demonstrated the efficacy of ofloxacin in the treatment of lower respiratory tract infections, urinary tract infections, and sexually transmitted diseases. Adverse effects to ofloxacin are usually mild and include gastrointestinal, central nervous system, and hypersensitivity reactions. Also available in solution for treatment of otic and ophthalmic bacterial infections.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2764544
Curator's Comment: Ofloxacin readily diffuses into CSF.
There is a case report that ofloxacin could induce hallucinations.
https://www.ncbi.nlm.nih.gov/pubmed/23716899
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3032098 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | OFLOXACIN, TABLET; ORAL Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets and other antibacterial drugs, ofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Ofloxacin tablets are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations.
Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae or Streptococcus pneumoniae.
Community-acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae.
Uncomplicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis.
Acute, uncomplicated urethral and cervical gonorrhea due to Neisseria gonorrhoeae. (See WARNINGS.)
Nongonococcal urethritis and cervicitis due to Chlamydia trachomatis. (See WARNINGS.)
Mixed Infections of the urethra and cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae. (See WARNINGS.)
Acute pelvic inflammatory disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae. (See WARNINGS.)
NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered.
Uncomplicated cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa .
Complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus or Pseudomonas aeruginosa.
Prostatitis due to Escherichia coli.
Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin. Therapy with ofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.
As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. Launch Date1.13944324E12 |
|||
Curative | OFLOXACIN, SOLUTION/DROPS; OTIC Approved UseOfloxacin otic solution 0.3% is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below:
Otitis Externa in adults and pediatric patients, 6 months and older, due to Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus.
Chronic Suppurative Otitis Media in patients 12 years and older with perforated tympanic membranes due to Proteus mirabilis, Pseudomonas aeruginosa, and Staphylococcus aureus.
Acute Otitis Media in pediatric patients one year and older with tympanostomy tubes due to Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa, Staphylococcus aureus,and Streptococcus pneumoniae. Launch Date1.19085125E12 |
|||
Curative | OFLOXACIN, SOLUTION/DROPS; OPHTHALMIC Approved UseOfloxacin ophthalmic solution, USP is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below:
CONJUNCTIVITIS due to: Gram-positive bacteria (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumonia); Gram-negative bacteria (Enterobacter cloacae, Haemophilus influenza, Proteus mirabilis, Pseudomonas aeruginosa)
CORNEAL ULCERS due to: Gram-positive bacteria (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumonia); Gram-negative bacteria (Pseudomonas aeruginosa, Serratia marcascens), Anaerobic species (Propionibacterium acnes) Launch Date1.36710717E12 |
|||
Curative | OFLOXACIN, SOLUTION/DROPS; OPHTHALMIC Approved UseOfloxacin ophthalmic solution, USP is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below:
CONJUNCTIVITIS due to: Gram-positive bacteria (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumonia); Gram-negative bacteria (Enterobacter cloacae, Haemophilus influenza, Proteus mirabilis, Pseudomonas aeruginosa)
CORNEAL ULCERS due to: Gram-positive bacteria (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumonia); Gram-negative bacteria (Pseudomonas aeruginosa, Serratia marcascens), Anaerobic species (Propionibacterium acnes) Launch Date1.36710717E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.5 μg/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
OFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.4 μg/mL |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
OFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.9 μg/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
OFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4.6 μg/mL |
400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
OFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
41.2 μg × h/mL |
400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
OFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
43.5 μg × h/mL |
400 mg 1 times / day steady-state, intravenous dose: 400 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
OFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
14.1 μg × h/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
OFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
21.2 μg × h/mL |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
OFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
31.4 μg × h/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
OFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
61 μg × h/mL |
400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
OFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
22.5 h |
400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
OFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
68% |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
OFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
20 mg/kg 1 times / day steady, oral (max) Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: |
unhealthy, 0 - 15 years n = 55 Health Status: unhealthy Condition: multidrug-resistant tuberculosis Age Group: 0 - 15 years Sex: M+F Population Size: 55 Sources: |
Other AEs: Traumatic injury, Headache... Other AEs: Traumatic injury (grade 1, 1 patient) Sources: Headache (grade 1, 1 patient) Insomnia (grade 2, 2 patients) Malaise and fatigue (grade 1, 1 patient) Nausea (grade 1, 2 patients) Vomiting (grade 1, 4 patients) Reaction skin (grade 1, 1 patient) Pruritus (grade 1, 4 patients) ALT (grade 1, 4 patients) ALT (grade 2, 1patients) |
3 g single, intravenous Overdose |
unhealthy, 26 years n = 1 Health Status: unhealthy Condition: acute left-upper-lobe pneumonia, asthma Age Group: 26 years Sex: F Population Size: 1 Sources: |
Disc. AE: CNS disorder (NOS)... AEs leading to discontinuation/dose reduction: CNS disorder (NOS) (1 patient) Sources: |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Co-administed with:: venlafaxine(75 mg) Sources: |
unhealthy, 43 years n = 1 Health Status: unhealthy Condition: upper respiratory tract infection Age Group: 43 years Sex: M Population Size: 1 Sources: |
Disc. AE: Orofacial dyskinesia... AEs leading to discontinuation/dose reduction: Orofacial dyskinesia (1 patient) Sources: |
400 mg 1 times / day steady, oral (max) Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, 81 years n = 1 Health Status: unhealthy Condition: urinary infections Age Group: 81 years Sex: F Population Size: 1 Sources: |
Other AEs: Psychiatric symptom NOS... |
300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
healthy, adult n = 12 Health Status: healthy Age Group: adult Sex: M Population Size: 12 Sources: |
|
400 mg single, oral |
healthy, adult n = 525 Health Status: healthy Condition: induced first-trimester abortions Age Group: adult Sex: F Population Size: 525 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Headache | grade 1, 1 patient | 20 mg/kg 1 times / day steady, oral (max) Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: |
unhealthy, 0 - 15 years n = 55 Health Status: unhealthy Condition: multidrug-resistant tuberculosis Age Group: 0 - 15 years Sex: M+F Population Size: 55 Sources: |
Malaise and fatigue | grade 1, 1 patient | 20 mg/kg 1 times / day steady, oral (max) Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: |
unhealthy, 0 - 15 years n = 55 Health Status: unhealthy Condition: multidrug-resistant tuberculosis Age Group: 0 - 15 years Sex: M+F Population Size: 55 Sources: |
Reaction skin | grade 1, 1 patient | 20 mg/kg 1 times / day steady, oral (max) Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: |
unhealthy, 0 - 15 years n = 55 Health Status: unhealthy Condition: multidrug-resistant tuberculosis Age Group: 0 - 15 years Sex: M+F Population Size: 55 Sources: |
Traumatic injury | grade 1, 1 patient | 20 mg/kg 1 times / day steady, oral (max) Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: |
unhealthy, 0 - 15 years n = 55 Health Status: unhealthy Condition: multidrug-resistant tuberculosis Age Group: 0 - 15 years Sex: M+F Population Size: 55 Sources: |
Nausea | grade 1, 2 patients | 20 mg/kg 1 times / day steady, oral (max) Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: |
unhealthy, 0 - 15 years n = 55 Health Status: unhealthy Condition: multidrug-resistant tuberculosis Age Group: 0 - 15 years Sex: M+F Population Size: 55 Sources: |
ALT | grade 1, 4 patients | 20 mg/kg 1 times / day steady, oral (max) Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: |
unhealthy, 0 - 15 years n = 55 Health Status: unhealthy Condition: multidrug-resistant tuberculosis Age Group: 0 - 15 years Sex: M+F Population Size: 55 Sources: |
Pruritus | grade 1, 4 patients | 20 mg/kg 1 times / day steady, oral (max) Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: |
unhealthy, 0 - 15 years n = 55 Health Status: unhealthy Condition: multidrug-resistant tuberculosis Age Group: 0 - 15 years Sex: M+F Population Size: 55 Sources: |
Vomiting | grade 1, 4 patients | 20 mg/kg 1 times / day steady, oral (max) Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: |
unhealthy, 0 - 15 years n = 55 Health Status: unhealthy Condition: multidrug-resistant tuberculosis Age Group: 0 - 15 years Sex: M+F Population Size: 55 Sources: |
ALT | grade 2, 1patients | 20 mg/kg 1 times / day steady, oral (max) Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: |
unhealthy, 0 - 15 years n = 55 Health Status: unhealthy Condition: multidrug-resistant tuberculosis Age Group: 0 - 15 years Sex: M+F Population Size: 55 Sources: |
Insomnia | grade 2, 2 patients | 20 mg/kg 1 times / day steady, oral (max) Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: |
unhealthy, 0 - 15 years n = 55 Health Status: unhealthy Condition: multidrug-resistant tuberculosis Age Group: 0 - 15 years Sex: M+F Population Size: 55 Sources: |
CNS disorder (NOS) | 1 patient Disc. AE |
3 g single, intravenous Overdose |
unhealthy, 26 years n = 1 Health Status: unhealthy Condition: acute left-upper-lobe pneumonia, asthma Age Group: 26 years Sex: F Population Size: 1 Sources: |
Orofacial dyskinesia | 1 patient Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Co-administed with:: venlafaxine(75 mg) Sources: |
unhealthy, 43 years n = 1 Health Status: unhealthy Condition: upper respiratory tract infection Age Group: 43 years Sex: M Population Size: 1 Sources: |
Psychiatric symptom NOS | 1 patient | 400 mg 1 times / day steady, oral (max) Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, 81 years n = 1 Health Status: unhealthy Condition: urinary infections Age Group: 81 years Sex: F Population Size: 1 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
no | ||||
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Evaluation of various methods of susceptibility to ofloxacin in strains of Mycobacterium tuberculosis. | 1999 Dec |
|
The use of levofloxacin in the treatment of respiratory tract infection. | 2000 Oct |
|
Levofloxacin-induced allergic interstitial nephritis. | 2000 Oct |
|
Anti-toxoplasma activities of 24 quinolones and fluoroquinolones in vitro: prediction of activity by molecular topology and virtual computational techniques. | 2000 Oct |
|
Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening. | 2000 Oct |
|
In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. | 2000 Sep |
|
Antibiotic susceptibility, serum response and surface properties of Klebsiella species. | 2001 |
|
Antibiotic use and development of resistance in blood culture isolates: 8 years of experience from a cancer referral center. | 2001 Apr |
|
Oral fluoroquinolone therapy results in drug adsorption on ureteral stents and prevention of biofilm formation. | 2001 Apr |
|
[Use of levofloxacine in primary care for outbreaks in COPD]. | 2001 Apr 15 |
|
Double-edged sword of chemosensitizer: increase of multidrug resistance protein (MRP) in leukemic cells by an MRP inhibitor probenecid. | 2001 Apr 27 |
|
Successful steroid therapy for cefdinir-induced acute tubulointerstitial nephritis with progressive renal failure. | 2001 Feb |
|
Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin. | 2001 Feb |
|
Rhodococcus equi and cytomegalovirus pneumonia in a renal transplant patient: diagnosis by fine-needle aspiration biopsy. | 2001 Feb |
|
Novel treatment of meningitis caused by multidrug-resistant Mycobacterium tuberculosis with intrathecal levofloxacin and amikacin: case report. | 2001 Feb 15 |
|
Effects of common topical otic preparations on the morphology of isolated cochlear outer hair cells. | 2001 Jan |
|
[In vitro antimycobacterial activities of a new quinolone, balofloxacin]. | 2001 Jan |
|
Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. | 2001 Jan |
|
Clinical, histopathological and bacteriological investigations in two cases of relapse following ROM treatment. | 2001 Mar |
|
Treatment of tularemia with levofloxacin. | 2001 Mar |
|
Antimicrobial activity of fluoroquinolone photodegradation products determined by parallel-line bioassay and high performance liquid chromatography. | 2001 Mar |
|
What have we learned from pharmacokinetic and pharmacodynamic theories? | 2001 Mar 15 |
|
In vitro activity of gemifloxacin against Streptococcus pneumoniae isolates in Germany. | 2001 Mar-Apr |
|
Abiotrophia bacteremia in a patient with neutropenic fever and antimicrobial susceptibility testing of Abiotrophia isolates. | 2001 May 15 |
|
Methicillin-resistant staphylococci and ofloxacin-resistant bacteria from clinically healthy conjunctivas. | 2001 May-Jun |
|
Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center. | 2001 Spring |
Sample Use Guides
OFLOXACIN TABLETS: the usual dose of ofloxacin tablets is 200 mg to 400 mg orally every 12 h.
Ofloxacin Otic Solution 0.3% for otic use.
Otitis Externa:
Five drops (0.25 mL, 0.75 mg ofloxacin) instilled into the affected ear once daily for seven days (from 6 months to 13 years old patients).
Ten drops (0.5 mL, 1.5 mg ofloxacin) instilled into the affected ear once daily for seven days (for patients 13 years and older).
Acute Otitis Media in Pediatric Patients with Tympanostomy Tubes:
Five drops (0.25 mL, 0.75 mg ofloxacin) instilled into the affected ear twice daily for ten days.
Chronic Suppurative Otitis Media with Perforated Tympanic Membranes:
Ten drops (0.5 mL, 1.5 mg ofloxacin) instilled into the affected ear twice daily for fourteen days.
Ofloxacin solution 0.3% for topical ophthalmic use.
Bacterial conjunctivitis: Days 1 and 2 - Instill one to two drops every two to four hours in the affected eye(s); Days 3 through 7 - Instill one to two drops four times daily.
Bacterial corneal ulcer: Days 1 and 2 - Instill one to two drops into the affected eye every 30 minutes, while awake. Awaken at approximately four and six hours after retiring and instill one to two drops; Days 3 through 7 to 9 - Instill one to two drops hourly, while awake;
Days 7 to 9 through treatment completion - Instill one to two drops, four times daily.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3182468
antibacterial activity of ofloxacin depends on strain: Enterobacteriaceae (MIC less than or equal to 0.12 mg/l), Vibrio cholerae (MIC less than or equal to 0.015 mg/l), V. parahaemolyticus (MIC less than or equal to 0.12 mg/l) Aeromonas hydrophila (MIC less than or equal to 0.03 mg/l), Staphylococcus spp. (MIC less than or equal to 1mg/l), beta-haemolytic Streptococcus spp. (MIC less than or equal to 2 mg/l), Corynebacterium diphtheriae (MIC less than or equal to 1 mg/l) and Cory. jeikeium (MIC less than or equal to 2 mg/l), alpha- and non-haemolytic Streptococcus spp., Str. pneumoniae and Listeria monocytogenes (MIC less than or equal to 4 mg/l for all species) and Str. faecalis (MIC less than or equal to 8 mg/l), Clostridium perfringens (MIC less than or equal to 1 mg/l), Cl. difficile (MIC less than or equal to 16 mg/l), Chlamydia trachomatis SA2f (MIC less than or equal to 0.5 mg/l).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:53:59 UTC 2023
by
admin
on
Fri Dec 15 17:53:59 UTC 2023
|
Record UNII |
I2UWV315WA
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB03494MIG
Created by
admin on Fri Dec 15 17:53:59 UTC 2023 , Edited by admin on Fri Dec 15 17:53:59 UTC 2023
|
PRIMARY | |||
|
DBSALT002388
Created by
admin on Fri Dec 15 17:53:59 UTC 2023 , Edited by admin on Fri Dec 15 17:53:59 UTC 2023
|
PRIMARY | |||
|
I2UWV315WA
Created by
admin on Fri Dec 15 17:53:59 UTC 2023 , Edited by admin on Fri Dec 15 17:53:59 UTC 2023
|
PRIMARY | |||
|
100000085916
Created by
admin on Fri Dec 15 17:53:59 UTC 2023 , Edited by admin on Fri Dec 15 17:53:59 UTC 2023
|
PRIMARY | |||
|
189546
Created by
admin on Fri Dec 15 17:53:59 UTC 2023 , Edited by admin on Fri Dec 15 17:53:59 UTC 2023
|
PRIMARY | |||
|
DTXSID70922609
Created by
admin on Fri Dec 15 17:53:59 UTC 2023 , Edited by admin on Fri Dec 15 17:53:59 UTC 2023
|
PRIMARY | |||
|
118120-51-7
Created by
admin on Fri Dec 15 17:53:59 UTC 2023 , Edited by admin on Fri Dec 15 17:53:59 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |